Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zepatier for Hepatitis C in PWIDs in Community vs Academic Settings
NCT03093415Phase 4Completed
- Sponsor
- Oregon Health & Science University
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of elbasvir + grazoprevir in hepatitis C (HCV) (3 arms), sponsored by Oregon Health & Science University. Primary endpoint: Sustained Virologic Response at 12 weeks. Started May 2017; status: completed.
02
Drugs
elbasvir + grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03093415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093415.